Toshiba rolls out ultrasound upgrade
Toshiba American Medical Systems of Tustin, CA, last month introduced the next generation of its mid-range ultrasound scanners at the American College of Cardiology conference in New Orleans. PowerVision 6000edp (expanded digital performance) allows
Toshiba American Medical Systems of Tustin, CA, last month introduced the next generation of its mid-range ultrasound scanners at the American College of Cardiology conference in New Orleans. PowerVision 6000edp (expanded digital performance) allows users to select multifrequency tissue harmonics that best match the size of the patient and acoustic access, and incorporates technological advancements in Doppler performance and color maps for cardiac and vascular applications.
Other technologies available on the system include Toshibas version of harmonic imaging, called Flash Echo Imaging, and its latest version of Clear View Tissue Harmonics (CVTH). The company plans to provide the $30,000 PowerVision 6000edp as a free upgrade to facilities that already have PowerVision 6000 installed. Toshiba launched PowerVision 6000 last spring (SCAN 5/27/98).
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
